Novavax says Phase 3 trial of omicron-targeting COVID vaccine supports its use as a booster
Novavax Inc. NVAX, -1.88% said Tuesday a late-stage trial of its vaccine targeting the COVID…
Read MoreNovavax Inc. NVAX, -1.88% said Tuesday a late-stage trial of its vaccine targeting the COVID…
Read MoreThe Centers for Disease Control and Prevention has refuted claims that it’s planning to add…
Read MoreThe Centers for Disease Control and Prevention has refuted claims that it’s planning to add…
Read MorePfizer Inc. PFE, +3.06% said Thursday that it plans to sell the COVID-19 shot it…
Read MorePfizer Inc. PFE, +4.67% said Thursday that it plans to sell the COVID-19 shot it…
Read MoreAnother omicron subvariant was determined to have spread to more countries in the week through…
Read MoreAnother omicron subvariant was determined to have spread to more countries in the week through…
Read MoreA flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreA flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support…
Read MoreThe head of the World Health Organization made his strongest comments yet about the devastation…
Read More